Barr Pharmaceuticals

Source: seekingalpha.com --- 30 days ago
Barr Pharmaceuticals Inc. (BRL) Q2 FY08 Earnings Call Complete Story » ...

Source: seekingalpha.com --- 16 days ago
The M & A Researcher submits: First, this August 14 Financial Times article will be referenced as it essentially echoes this publication's original assessment of the Barr Pharmaceuticals (BRL) - Teva Pharmaceutical (TEVA) transaction upon announcement last month. Of particular interest in this piece are the following passages from an third-part analytical report: An analyst report by Sanford C. Bernstein Co dated 18 July outlines 13 overlaps where Teva and Barr own a majority of the market. For example, Chlorzoxazone is one product where Barr owns 52% of the market share and Teva 48%, with only five total competitors. Other drugs include Tetracycline (Barr: 11%, Teva: 88%, 10 total competitors); Ethosuximide (Barr: 63%, Teva: 25%, three total competitors) and Metronidazole (Barr: 44%, Teva: 38%, 26 total competitors). Complete Story » ...

Source: www.centredaily.com --- 18 days ago
Zacks Equity Research highlights Stone Energy Corp. (NYSE: SGY) as the Bull of the Day and American Axle (NYSE: AXL) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Avnet, Inc. (NYSE: AVT), Barr Pharmaceuticals (NYSE: BRL) and Rogers Communications (NYSE: RCI). ...

Source: www.fwicki.com --- 16 days ago
Barr Pharmaceuticals, Inc. today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration for its generic version of Pfizer Inc.'s Aredia ... ...

Source: israelplug.com --- 29 days ago
According to Haaretz, Teva has been going on a “little” shopping spree, buying companies as if they were cute pairs of shoes they just had to have. (And FYI, this Teva company has no connection to the Israeli hikers’ beloved Teva sandal co., incidentally made in China.) Recently, Teva purchased Barr Pharmaceuticals, “the fourth largest [...] ...

Source: www.drug-cancer.com --- 35 days ago
Cephalon Inc. said Thursday night it filed a patent infringement lawsuit earlier this week against Barr Pharmaceuticals Inc. ...

Source: articles.moneycentral.msn.com --- 34 days ago
Freddie Mac and Fannie Mae continued their fall; Rohm & Haas and Barr Pharmaceuticals jumped on buyout bids. ...

Source: news.yahoo.com --- 35 days ago
Investor's Business Daily - Teva Pharmaceutical's planned buyout of Barr Pharmaceuticals for cash and stock was a headline-grabber. ...

Source: online.wsj.com --- 26 days ago
Barr Pharmaceuticals agreed to settle two patent disputes with Boehringer over the German firm's medication for Parkinson's disease and for strokes. Barr also announced supply and promotion deals with Boehringer. ...

Source: online.wsj.com --- 8 days ago
Barr Pharmaceuticals said a federal court has invalidated a patent, clearing the way for the generic-drug maker to sell its version of Johnson & Johnson's Razadyne Alzheimer's drug. ...

Source: cincinnati.bizjournals.com --- 25 days ago
The settlement of a dispute between Barr Pharmaceuticals and Boehringer Ingelheim over generic drugs will benefit Barr subsidiary Duramed Pharmaceuticals. (BRL) ...

Source: cincinnati.bizjournals.com --- 30 days ago
Barr Pharmaceuticals Inc., helped by women’s health products from its Duramed subsidiary, boosted revenues and net income in the second quarter. (BRL) ...

Source: www.investors.com --- 33 days ago
Teva Pharmaceutical's planned buyout of Barr Pharmaceuticals for cash and stock was a headline-grabber. ...

Source: www.fiercepharma.com --- 9 days ago
Seven generics makers are high-fiving today after a federal judge declared Johnson & Johnson's patent on Alzheimer's med Razadyne invalid. The ruling is the latest development in a long-standing dispute over the patent that started when J&J sued the copycats to keep their versions off the market. Now, J&J says it will appeal the judge's decision, but Barr, for one, says it's going to launch its generics straight away. So does Mylan. The other generics makers involved are Teva-- which is buying Barr --plus Dr. Reddy's Laboratories, Par Pharmaceuticals, and units of Actavis and Merck KGaA. Razadyne accounted for $214 million of J&J's 2007 sales. - read J&J's Ortho-McNeil release - check out the story in the Star-Ledger - see the Interactive Investor news - get the Wall Street Journal article   Related Articles: FDA holds back approval for J&J schizophrenia med Genentech, J&J earnings expected to rise Patent 'cliff' looms for Big Pharma BMS is lead player in patent-approval race Does the patent cliff drive innovation? ...

Source: pr-gb.com --- 6 days ago
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) (galantamine hydrobromide), 4 mg, 8 mg and 12 mg tablets. Barr intends to launch its generic Razadyne tablets product immediately. Barr filed an Abbreviated New Drug Application (ANDA) with the U.S. Food Drug Administration (FDA) for Janssen's Razadyne (galantamine hydrobromide), 4 mg, 8 mg and 12 mg tablets on February 28,... ...

Source: burbsbiz.lohudblogs.com --- 31 days ago
Barr Pharmaceuticals Inc., the drug company that has operations in Pomona, earned $57 million, or 52 cents a share, in the second quarter, compared with a profit of $45 million, or 41 cents a share, a year earlier. Revenues rose to $779 million, from $634 million. Barr, which is based in Montvale, N.J., has its Barr Laboratories [...] ...

Source: www.vabio.org --- 31 days ago
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced July 18 that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide for... ...

Source: www.fwicki.com --- 32 days ago
MONTVALE, N.J., July 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent ... ...

Source: www.fwicki.com --- 32 days ago
MONTVALE, N.J., July 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in ... ...

Source: www.topix.com --- 29 days ago
Partnering is increasingly the choice for securing market share and business growth... ... Teva's recent acquisition of Barr Pharmaceuticals may be the latest headline grabbing deal, but industry and commerce ... ...